Trials and Fibrillations with Dr John Mandrola

Are US Electrophysiologists Too Easily Impressed? Electrophysiologists adopt new things a little too enthusiastically, writes John Mandrola, MD, of a new technique to treat atrial fibrillation.
Commentary, July 17, 2024
Is Red Meat Healthy? Multiverse Analysis Has Lessons Beyond Meat Is red meat bad for you? A multiverse analysis shows that the answer varies by analytic method. The takeaway beyond meat is that this approach should be used for most observational research.
Commentary, May 09, 2024
EMPACT-MI: Another SGLT2 Inhibitor Miss Post-MI Empagliflozin added to standard care did not improve outcomes in post-MI patients at risk for heart failure. John Mandrola, MD, sees the diminishing returns for add-on drugs as positive for patients.
Experts And Viewpoints, April 12, 2024
ACC 2024 Preventive Coronary Stents: Not There Yet The PREVENT trial on stenting stable plaques deemed vulnerable by imaging criteria suggests a benefit over medical therapy alone. John Mandrola, MD, finds it provocative but not yet ready to act on.
Commentary, April 11, 2024
ACC 2024 Beta-Blockers Post-MI Past Their Expiration Date: REDUCE-AMI REDUCE-AMI showed no benefit for routine beta-blockers post–MI in patients with normal ejection fraction. John Mandrola, MD, asks: Does evidence-based medicine need expiration dates?
Experts And Viewpoints, April 08, 2024
ACC 2024 Impella Saves Lives in CS, but Patient Selection Key In the first randomized trial of Impella in a select group of patients with AMI and cardiogenic shock, the device saved lives. The high rate of serious adverse events calls us to pay attention to the nuances of the data, says John Mandrola, MD.
Experts And Viewpoints, April 07, 2024
Mandrola's Three Trials to Look For at the 2024 ACC Trials on chelation therapy, the Impella device, and beta-blockers are cardiologist John Mandrola's picks for the upcoming American College of Cardiology Meeting in Atlanta.
Experts And Viewpoints, April 02, 2024
Food As Medicine: A Great Idea That Didn't Work Even laudable, plausible concepts have to be thoroughly tested, writes John Mandrola, MD.
Experts And Viewpoints, February 22, 2024
Mandrola's Top 10 Cardiology Stories of 2023 Obesity drugs, factor XI inhibitors, and procedures such as TAVR, PCI, and TEER are among the top stories of 2023, according to cardiologist John Mandrola, MD.
Experts And Viewpoints, December 20, 2023
AHA 2023 ARTESIA Doesn't Answer a Common Question in Cardiology The trial on apixaban vs aspirin in subclinical atrial fibrillation did not provide an easy answer on whether to anticoagulate patients with these common arrhythmias, writes John Mandrola, MD.
Experts And Viewpoints, November 15, 2023
AHA 2023 ORBITA-2 Saves Interventional Cardiology, Questions Guidance The second sham-controlled trial of PCI in stable CAD brings relief to the field but challenges our understanding of angina and raises the bar for trials in other specialties, says John Mandrola, MD.
Experts And Viewpoints, November 13, 2023
AHA 2023 Positive Results From SELECT Begins a New Era in Cardiology The GLP-1 agonist lowered cardiovascular events in overweight patients with CVD. While questions remain on how it works, this cardiologist sees this as a call to change societal norms around obesity.
Experts And Viewpoints, November 12, 2023
AHA 2023 Mandrola's Top Trials to Look for at AHA 2023 Semaglutide’s cardiovascular benefit in SELECT, another sham-PCI trial from the ORBITA investigators, and ARTESiA, which examines anticoagulation in subclinical atrial fibrillation, are the top AHA late-breakers for John Mandrola, MD.
Experts And Viewpoints, November 07, 2023
The Most Important Study From ESC If you treat patients, no trial at ESC is more important, according to John Mandrola, MD. The results of FRAIL-AF demonstrate the value of humility in science and the practice of evidence-based medicine.
Experts And Viewpoints, September 01, 2023
ESC 2023 AF Ablation in End-Stage HF: Too Good to Be True? Patients with AF and end-stage heart failure saw a dramatic early benefit from ablation. Some question the findings but others see a subset of patients for whom sinus rhythm makes a big difference.
Experts And Viewpoints, August 30, 2023
ESC 2023 Pulsed Field Ablation for AF Underwhelming in ADVENT Pulsed field ablation did not live up to the hype and enthusiasm of European colleagues, according to this US-based electrophysiologist, but the results of ADVENT are likely sufficient for FDA approval.
Experts And Viewpoints, August 28, 2023
ESC 2023 Supporting Evidence for a Common Practice John Mandrola, MD, reviews BUDAPEST CRT from ESC 2023, which supports the practice of upgrading patients with pacing-induced heart failure to cardiac resynchronization therapy.
Experts And Viewpoints, August 27, 2023
ESC 2023 Semaglutide in HFpEF Cleared a Low Bar Patients with heart failure with preserved ejection fraction and obesity lost weight and felt better while taking semaglutide vs placebo, but was the bar for success set too low in STEP-HFpEF?
Experts And Viewpoints, August 26, 2023
ESC 2023 How Much AF Warrants Anticoagulation? Electrophysiologist John Mandrola reviews the NOAH-AFNET 6 trial presented at the European Society of Cardiology Congress 2023, which compared edoxaban vs placebo in patients with atrial high-rate episodes.
Experts And Viewpoints, August 26, 2023
ESC 2023 Mandrola's 5 Things to Look for at ESC 2023 Electrophysiologist John Mandrola, MD, picks his top trials and themes from the upcoming European Society of Cardiology congress in Amsterdam.
Experts And Viewpoints, August 21, 2023

No Results